1. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. (27th August 2018) Authors: Sabari, J K; Leonardi, G C; Shu, C A; Umeton, R; Montecalvo, J; Ni, A; Chen, R; Dienstag, J; Mrad, C; Bergagnini, I; Lai, W V; Offin, M; Arbour, K C; Plodkowski, A J; Halpenny, D F; Paik, P K; Li, B T; Riely, G J; Kris, M G; Rudin, C M Journal: Annals of oncology Issue: Volume 29:Number 10(2018) Page Start: 2085 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. (20th March 2019) Authors: Li, B T; Janku, F; Jung, B; Hou, C; Madwani, K; Alden, R; Razavi, P; Reis-Filho, J S; Shen, R; Isbell, J M; Blocker, A W; Eattock, N; Gnerre, S; Satya, R V; Xu, H; Zhao, C; Hall, M P; Hu, Y; Sehnert, A J; Brown, D Journal: Annals of oncology Issue: Volume 30:Number 4(2019) Page Start: 597 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗